Cargando…
埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
BACKGROUND AND OBJECTIVE: Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Ic...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999815/ https://www.ncbi.nlm.nih.gov/pubmed/27118647 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04 |
_version_ | 1783331518379196416 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Icotinb is China's first EGFR-TKI with independent intellectual property rights. The aim of this study is to investigate the clinical characteristics about the beneficiary of advanced NSCLC patients with EGFR Common mutation who were treated with Icotinib. Retrospectively collect the data about beneficiary [progression-free survival (PFS)≥6 months] and analysis of the related risk factors for prognosis. METHODS: From September 1, 2011 to September 30, 2015, 231 cases of advanced NSCLC beneficiary with EGFR common mutation were enrolled for treatment with icotinib in Zhejiang Cancer Hospital. RESULTS: The one year benefit rate was 67.9% in the group treated with Icotinib as first line, and in the groupas second line or above was 53.6%, which is statisticallysignificant. The two years benefit rate was 18.7% and 9.3%, respectively. The median PFS of first line group and the second line or above was 16.7 and 12.4 months, respectively. The presence of brain metastasis (P=0.010), Prior chemotherapy (P=0.001), Eastern Cooperative Oncology Group (ECOG) score (P=0.001) were the main factors influencing the prognosis. The most common adverse were skin rashes (51 cases, 22.1%) and diarrhea (27 cases, 11.7%). CONCLUSION: Icotinib offers long-term clinical benefit and good tolerance for advanced NSCLC harboring EGFR gene mutation. Its advantage groups in addition to the patients with brain metastases and better ECOG score, the curative effect of patients with the first-line treatment is superior to second or further line. |
format | Online Article Text |
id | pubmed-5999815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59998152018-07-06 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Icotinb is China's first EGFR-TKI with independent intellectual property rights. The aim of this study is to investigate the clinical characteristics about the beneficiary of advanced NSCLC patients with EGFR Common mutation who were treated with Icotinib. Retrospectively collect the data about beneficiary [progression-free survival (PFS)≥6 months] and analysis of the related risk factors for prognosis. METHODS: From September 1, 2011 to September 30, 2015, 231 cases of advanced NSCLC beneficiary with EGFR common mutation were enrolled for treatment with icotinib in Zhejiang Cancer Hospital. RESULTS: The one year benefit rate was 67.9% in the group treated with Icotinib as first line, and in the groupas second line or above was 53.6%, which is statisticallysignificant. The two years benefit rate was 18.7% and 9.3%, respectively. The median PFS of first line group and the second line or above was 16.7 and 12.4 months, respectively. The presence of brain metastasis (P=0.010), Prior chemotherapy (P=0.001), Eastern Cooperative Oncology Group (ECOG) score (P=0.001) were the main factors influencing the prognosis. The most common adverse were skin rashes (51 cases, 22.1%) and diarrhea (27 cases, 11.7%). CONCLUSION: Icotinib offers long-term clinical benefit and good tolerance for advanced NSCLC harboring EGFR gene mutation. Its advantage groups in addition to the patients with brain metastases and better ECOG score, the curative effect of patients with the first-line treatment is superior to second or further line. 中国肺癌杂志编辑部 2016-04-20 /pmc/articles/PMC5999815/ /pubmed/27118647 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 |
title | 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 |
title_full | 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 |
title_fullStr | 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 |
title_full_unstemmed | 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 |
title_short | 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 |
title_sort | 埃克替尼治疗egfr敏感突变的晚期非小细胞肺癌获益患者的临床分析 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999815/ https://www.ncbi.nlm.nih.gov/pubmed/27118647 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04 |
work_keys_str_mv | AT āikètìnízhìliáoegfrmǐngǎntūbiàndewǎnqīfēixiǎoxìbāofèiáihuòyìhuànzhědelínchuángfēnxī AT āikètìnízhìliáoegfrmǐngǎntūbiàndewǎnqīfēixiǎoxìbāofèiáihuòyìhuànzhědelínchuángfēnxī AT āikètìnízhìliáoegfrmǐngǎntūbiàndewǎnqīfēixiǎoxìbāofèiáihuòyìhuànzhědelínchuángfēnxī |